Results 311 to 320 of about 619,710 (391)

Considerations for drug trials in hypertrophic cardiomyopathy

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant   +17 more
wiley   +1 more source

Topobexin targets the Topoisomerase II ATPase domain for beta isoform-selective inhibition and anthracycline cardioprotection. [PDF]

open access: yesNat Commun
Kubeš J   +20 more
europepmc   +1 more source

Sacubitril/valsartan preserves regional cardiac function following myocardial infarction in rats

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1304-1315, April 2025.
Parts of the figure were drawn by using pictures from Servier Medical Art. Servier Medical Art by Servier is licensed under a Creative Commons Attribution 3.0 Unported License (https://creativecommons.org/licenses/by/3.0/). Abstract Aims Sacubitril/valsartan (Sac/Val) is used for treatment of heart failure. The effect of Sac/Val on regional dysfunction
Einar Sjaastad Nordén   +16 more
wiley   +1 more source

Epac1 increases myosin regulatory light-chain phosphorylation, energetic cost of contraction, and susceptibility to heart failure. [PDF]

open access: yesPLoS One
Ohnuki Y   +12 more
europepmc   +1 more source

Semaglutide normalizes increased cardiomyocyte calcium transients in a rat model of high fat diet‐induced obesity

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1386-1397, April 2025.
Sequeira et al. reveal how the glucagon‐like peptide‐1 receptor agonist (GLP‐1‐RA) semaglutide restores cardiomyocyte function in rats subjected to a high‐fat/high‐fructose diet (HFD). Employing fluorescence‐ and patch‐clamp technology in isolated cardiac myocytes, they demonstrate that semaglutide reverses HFD‐induced activation of L‐type calcium ...
Vasco Sequeira   +12 more
wiley   +1 more source

TOT3-AHA1 module: its role in fine-tuning stomatal responses. [PDF]

open access: yesFront Plant Sci
Gong L   +6 more
europepmc   +1 more source

Discovering new hub genes of dilated cardiomyopathy

open access: yesESC Heart Failure, EarlyView.
Abstract Aims Dilated cardiomyopathy (DCM) has a poor prognosis and exhibits a complex and diverse aetiology and genetic profile. The genes responsible for the pathogenesis of DCM have not been fully identified. The present study aimed to explore new hub genes of DCM by mining the human DCM databases and further by experimental validation.
Jun‐Yan Zhu   +9 more
wiley   +1 more source

Cardioprotective effects of semaglutide on isolated human ventricular myocardium

open access: yesEuropean Journal of Heart Failure, EarlyView.
Semaglutide reduces late sodium current (INa) and diastolic calcium (Ca) sparks in human cardiomyocytes from aortic stenosis (AS) and end‐stage heart failure with reduced ejection fraction (HFrEF) patients, thereby increasing Ca transients. Improved Ca storage may underly the enhanced contractility of human cardiomyocytes upon semaglutide.
Thomas Krammer   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy